Agios Pharmaceuticals AGIO Estimates

NASDAQ AGIO
$33.33 +0.19 (+0.59%)
As of: Sep 4, 2026 · 11:47 AM EDT
Analyst Estimates

Agios Pharmaceuticals, Inc. Revenue Estimates

Periods 26
Next Period Q3 26
Consensus 48.80 M

Analysts expect Agios Pharmaceuticals, Inc. to report revenue of 48.80 M for Q3 26, against a range of 46.52 M to 51.07 M. The most recent reported quarter, Q2 26, came in at 44.74 M, a 60.6% beat against the 27.86 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 9.00 M10.70 M8.70 M12.50 M12.90 M19.97 M20.75 M44.74 M--------
High Estimate 10.58 M9.15 M9.75 M10.54 M11.47 M12.45 M14.38 M29.82 M51.07 M69.91 M76.29 M91.50 M89.82 M104.49 M114.94 M125.95 M
Low Estimate 9.20 M8.59 M8.65 M9.73 M10.78 M10.43 M12.97 M25.89 M46.52 M58.23 M65.45 M85.06 M76.64 M91.30 M96.60 M106.21 M
Consensus Estimate 9.89 M8.87 M9.20 M10.14 M11.12 M11.44 M13.67 M27.86 M48.80 M64.07 M70.87 M88.28 M83.23 M97.90 M105.77 M116.08 M
Analyst Estimates

Agios Pharmaceuticals, Inc. Earnings Per Share (EPS) Estimates

Periods 26
Next Period Q3 26
Consensus -1.21

Analysts expect Agios Pharmaceuticals, Inc. to report earnings per share of -1.21 for Q3 26, against a range of -1.32 to -1.10. The most recent reported quarter, Q2 26, came in at -1.69, a 6.3% miss against the -1.59 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 16.22-1.44-1.55-1.93-1.78-1.86-1.69-1.69--------
High Estimate 16.60-1.49-1.55-1.62-1.79-1.96-1.54-1.44-1.10-1.18-1.06-0.85-2.34-3.810.581.41
Low Estimate 15.30-1.73-1.75-1.90-2.17-2.16-1.86-1.74-1.32-1.28-1.16-0.97-2.86-4.430.521.29
Consensus Estimate 15.95-1.61-1.65-1.76-1.98-2.06-1.70-1.59-1.21-1.23-1.11-0.91-2.60-4.120.551.35